Scientific Article

Should Sentinel Lymph Node Biopsy Status Guide Adjuvant Radiation Therapy in Patients With Merkel Cell Carcinoma?

Tessnim R. Ahmad, MD,a Harish N. Vasudevan, MD, PhD,b Ann A. Lazar, PhD,c Jason W. Chan, MD,b Jonathan R. George, MD,d Michael D. Alvarado, MD,e Siegrid S. Yu, MD,f Adil Daud, MD,g and Sue S. Yom, MD, PhD, MASb,*

aDepartment of Ophthalmology, University of California San Francisco, San Francisco, California; bDepartment of Radiation Oncology, University of California San Francisco, San Francisco, California; cDepartment of Preventative and Restorative Dental Sciences, University of California San Francisco, San Francisco, California; dDepartment of Otolaryngology - Head and Neck Surgery, University of California San Francisco, San Francisco, California; eDepartment of Surgery, University of California San Francisco, San Francisco, California; fDepartment of Dermatology, University of California San Francisco, San Francisco, California; gDepartment of Medicine, University of California San Francisco, San Francisco, California

Received March 28, 2021; accepted July 13, 2021

Abstract

Purpose: Radiation of the draining lymph node basin remains controversial for Merkel cell carcinoma, particularly in the era of sentinel lymph node biopsy (SLNB).

Methods and Materials: Based on a 20-year experience using SLNB-guided adjuvant radiation therapy (RT), we conducted a retrospective review of clinically node-negative patients testing 2 hypotheses: (1) whether nodal RT could be safely omitted in SLNB-negative Merkel cell carcinoma and (2) whether the excised primary site should always be radiated. Clinically node-positive patients were excluded.

Results: Among 57 clinically node-negative patients who underwent SLNB and wide local excision (WLE), 42 (74%) had a negative SLNB, and 15 (26%) had a positive SLNB. At a median follow-up of 43 months (range, 5-182), SLNB-negative patients irradiated to the primary site had improved 4-year disease-specific survival (100% vs 65%, \( P = .008 \)), local recurrence-free survival (100% vs 76%, \( P = .009 \)), and distant recurrence-free survival (100% vs 75%, \( P = .008 \)), but not overall survival (87.5% vs 57.7%, \( P = .164 \)) compared with SLNB-positive patients receiving comprehensive RT. Among SLNB-negative patients treated with WLE only, 67% (6/9) had a disease relapse, half of which were local relapses (33%).

Conclusions: In this single-institution retrospective review, after negative SLNB and WLE, RT given only to the primary site provided 100% disease control without a need for nodal RT. Among SLNB-negative patients who had WLE, omission of postoperative primary-site RT was associated with 67% cancer relapse, of which half was local.

Sources of support: No funding was paid to the authors or their institutions for this work.

Disclosures: A.D. reports grants from Genentech, grants from Bristol-Myers Squibb, grants from Merck, grants from Incyte, grants from Checkmate, grants from OncoSec, personal fees from Array, personal fees from Pfizer, grants from Xencor, grants from Curis, grants from Novartis outside the submitted work. S.S.Y. reports grants from Genentech, Bristol-Myers Squibb, Merck, and BioMimetiX, personal fees from Springer and UpToDate, and other from ASTRO outside the submitted work.

*Corresponding author: Sue S. Yom, MD, PhD, MAS; E-mail: Sue.Yom@ucsf.edu

https://doi.org/10.1016/j.adro.2021.100764

2452-1094/© 2021 The Author(s). Published by Elsevier Inc, on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor that occurs predominantly in the sun-exposed skin of older Caucasian patients.\(^1\) The majority of cases are associated with the Merkel cell polyomavirus, and risk factors include ultraviolet radiation exposure and immunosuppression.\(^1\) From 2000 to 2013, MCC incidence increased 95% with an estimated 2800 new diagnoses in 2020 in the United States, reflecting an aging population.\(^2\) Outcomes remain poor with a 5-year disease-specific survival of 64%.\(^3\)

Sentinel lymph node biopsy (SLNB) and wide local excision (WLE) comprise the standard initial management approach followed by adjuvant radiation therapy (RT) to the primary tumor site.\(^4\) On the other hand, indications for RT to the draining lymph node basin are less clear. Some studies suggest adjuvant nodal RT can be safely omitted in SLNB-negative disease, citing low rates of regional recurrence.\(^3,5-7\) However, other studies demonstrate regional recurrence rates as high as 33% even in SLNB-negative patients, raising concern about the draining lymph nodes in this population.\(^2,22\)

Here, we report a 20-year experience treating MCC with adjuvant RT according to a policy of excluding the draining nodal basin for SLNB-negative MCC and including the draining nodal basin for SLNB-positive MCC. The goal of this report was specifically to evaluate two hypotheses: (1) if nodal RT could be safely omitted in SLNB-negative MCC and (2) if the excised primary site should always be radiated.

Methods and Materials

Procedures

Institutional review board approval was obtained. We identified clinically node-negative patients who underwent SLNB and WLE for MCC between March 1996 and December 2015. The closing date for patient record review was selected to allow for adequate follow-up time. Data were obtained from the institutional cancer registry and radiation oncology department records.

Patients underwent WLE of the primary tumor to establish negative histologic margins except in cases of limitations on resectability. Regional staging via SLNB was performed at the time of WLE, with completion lymph node dissection in cases of positive SLNB. Sentinel lymph node detection used a gamma probe after peritumoral injection of a radiotracer. The dissection was deemed complete when the activity in the surgical bed was less than 10% of the initially detected activity of the most active node. Adjuvant RT to the primary tumor site was recommended for all patients and given to the draining lymph node basin for SLNB-positive patients. RT consisted of 46 to 50 Gy in 23 to 25 fractions. Patients with positive margins were treated to a dose of 60 Gy in 30 fractions. Primary site irradiation almost always consisted of relatively superficial electron beam therapy, and the nodal basin was irradiated separately with a 3-dimensional conformal photon plan. After 2010, intensity-modulated RT was frequently used to treat draining nodal basins. If the primary site was in immediate anatomic proximity to the draining nodal basin and both were to be irradiated, intensity-modulated RT was used to treat both areas.

Statistical analysis

Demographic and clinical covariates included: age (continuous), sex, race (Caucasian, non-Caucasian), primary site (head and neck [HN] vs non-HN), primary size ($\leq2$ cm vs $>2$ cm, grouped at the median based on $p_T$ stage), American Joint Committee on Cancer (AJCC) prognostic group (I/II vs III/IV), number of pathologically involved lymph nodes ($\leq1$ vs $>1$, grouped at the median for SLNB-positive patients), and number of regional nodes examined ($\leq3$ vs $>3$, grouped at the median for all patients). Dichotomization of AJCC prognostic group resulted in an equivalent variable to SLNB status. Outcomes included death, local recurrence (arising within or adjacent to primary excision site), regional recurrence (arising in draining lymph node basin or in-transit), or distant recurrence (metastasis). Survival endpoints included overall survival (OS), disease-specific survival ([DSS] defined as death due to MCC), local recurrence-free survival (LRFS), regional recurrence-free survival, and distant recurrence-free survival (DRFS).

Survival time was calculated from the date of diagnosis. Descriptive data were summarized and compared using Fisher’s exact test and $t$ test. Survival endpoints were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis, including propensity score, was not possible because there were less than 10 events.\(^8\) Two-sided $P$ values less than .05 were considered statistically significant. Data were analyzed using STATA software version 15 (StataCorp, College Station, TX).
Results

Patient and treatment characteristics

Over the study period, 183 patients treated for MCC were identified. We excluded patients with clinically-positive nodes (n = 19), WLE without SLNB (n = 57), and inconclusive AJCC staging (n = 27), as these patients were treated per different clinical algorithms. Of the remaining 80 patients in the dataset, 23 were excluded owing to: inadequate treatment information contained in older records (12); unavailable outside records (4); non-standard treatments (3 chemotherapy only, 1 surgery and chemotherapy, 1 RT only, and 1 hospice shortly after surgery); and inconclusive SLNB (1).

Of the remaining 57 patients who underwent WLE and SLNB, 42 (74%) had a negative SLNB and 15 (26%) had a positive SLNB. Thirty-three (79%) SLNB-negative patients underwent adjuvant RT to the primary site only and 9 (21%) were observed. Thirteen (87%) SLNB-positive patients underwent RT to the primary site plus nodal basin and 2 (13%) were observed. Figure 1 is a diagram summarizing SLNB status and subsequent treatment. The median age at diagnosis was 70 years (range, 43-89), and most patients were male (n = 33, 58%). The most common primary location was in the head and neck (n = 28, 49%). Demographic and clinical characteristics are summarized in Table 1. There were no significant differences in patient age, sex, race, polyomavirus positivity, anatomical site, tumor size, and number of nodes examined between SLNB-positive and SLNB-negative patients and between patients treated with or without adjuvant radiation. However, SLNB-positive patients were more likely than SLNB-negative patients to be immunosuppressed ($P = .016$) and to have a higher AJCC prognostic group and number of positive nodes ($P < .001$).

Recurrence and survival outcomes

Among the 57 patients treated with WLE and SLNB, there were a total of 11 recurrences (19%), including 7 patients (64%) observed after WLE and 4 SLNB-positive patients (36%) treated with adjuvant radiation to the primary site and nodal basin. Among patients treated with WLE only, the proportion of SLNB-negative patients (n = 9) who had any disease failure was 67% (n = 6); 3 (33%) had local relapse and 2 (22%) had regional relapse. One of the 2 (50%) SLNB-positive patients observed after WLE had a distant relapse. Table 2 enumerates the recurrences by treatment modality.

SLNB-negative patients, who were irradiated to the primary site only, had improved 4-year DSS (100% vs 65%, $P = .008$), LRFS (100% vs 76%, $P = .009$), and DRFS (100% vs 75%, $P = .008$), but not OS (87.5% vs 87.5%).
| Characteristic | SLNB-negative | All SLNB-negative | SLNB-positive | All SLNB-positive | All SLNB |
|---------------|---------------|------------------|---------------|------------------|---------|
| n             | 33 (79)       | 9 (21)           | 42            | 13 (87)          | 2 (13)  |
|               | 43 (5-128)    | 49 (14-97)       | 48 (5-128)    | 28 (1-182)       | 16 (7-25)|
| Median follow-up (range, months) | 68 (48-85) | 76 (52-85) | 69 (48-85) | 75 (43-89) | 75 (68-81) | 75 (43-89) | 70 (43-89) |
| Median age at diagnosis (range, years) | 68 (48-85) | 76 (52-85) | 69 (48-85) | 75 (43-89) | 75 (68-81) | 75 (43-89) | 70 (43-89) |
| Sex           |               |                  |               |                  |         |
| Male          | 16 (48)       | 7 (78)           | 23 (55)       | 8 (62)           | 2 (100) |
| Female        | 17 (52)       | 2 (22)           | 19 (45)       | 5 (38)           | 0 (0)   |
| Race          |               |                  |               |                  |         |
| Caucasian     | 31 (94)       | 9 (100)          | 40 (95)       | 9 (69)           | 2 (100) |
| Non-Caucasian | 2 (6)         | 0 (0)            | 2 (5)         | 3 (23)           | 0 (0)   |
| Unknown       | 0 (0)         | 0 (0)            | 0 (0)         | 1 (8)            | 0 (0)   |
| Immunosuppressed |         |                  |               |                  |         |
| Yes           | 4 (12)        | 1 (11)           | 5 (12)*       | 4 (31)           | 1 (50)  |
| No            | 26 (79)       | 7 (78)           | 33 (79) *     | 6 (46)           | 0 (0)   |
| Unknown       | 3 (9)         | 1 (11)           | 4 (10) *      | 3 (23)           | 1 (50)  |
| Polyomavirus  |               |                  |               |                  |         |
| Positive      | 7 (21)        | 1 (11)           | 8 (19)        | 2 (15)           | 0 (0)   |
| Negative      | 1 (3)         | 2 (22)           | 3 (7)         | 2 (15)           | 0 (0)   |
| Unknown       | 25 (76)       | 6 (67)           | 31 (74)       | 9 (69)           | 2 (100) |
| Primary tumor site |      |                  |               |                  |         |
| Head and neck | 16 (48)       | 4 (44)           | 20 (48)       | 8 (62)           | 0 (0)   |
| Trunk and buttocks | 5 (15) | 1 (11)           | 6 (14)        | 0 (0)            | 0 (0)   |
| Extremities   | 12 (36)       | 4 (44)           | 16 (38)       | 5 (38)           | 2 (100) |
| AJCC prognostic group |     |                  |               |                  |         |
| I             | 27 (82)       | 0 (0)            | 27 (64)       | 0 (0)            | 0 (0)   |
| II            | 6 (18)        | 0 (0)            | 6 (14)        | 0 (0)            | 0 (0)   |
| III           | 0 (0)         | 0 (0)            | 0 (0)         | 13 (100)         | 2 (100) |
| Pathologic T category |         |                  |               |                  |         |
| pT1           | 25 (76)       | 0 (0)            | 25 (60)       | 8 (62)           | 1 (50)  |
| pT2           | 5 (15)        | 0 (0)            | 5 (12)        | 1 (8)            | 0 (0)   |
| pT3           | 1 (3)         | 0 (0)            | 1 (2)         | 0 (0)            | 0 (0)   |
| pT4           | 1 (3)         | 0 (0)            | 1 (2)         | 1 (8)            | 0 (0)   |

(continued on next page)
| Characteristic | SLNB-negative | All SLNB-negative | SLNB-positive | All SLNB-positive | All SLNB |
|---------------|--------------|------------------|--------------|------------------|---------|
|               | Adjuvant radiation | No adjuvant radiation | Adjuvant radiation | No adjuvant radiation |         |
| Unknown       | 1 (3) | 3 (33) | 4 (10) | 3 (23) | 1 (50) | 4 (27) | 8 (14) |
| Total number of positive nodes | | | | | | | |
| 0             | 33 (100) | 9 (100) | 42 (100) | 0 (0) | 0 (0) | 0 (0) | 42 (74) |
| 1             | 0 (0) | 0 (0) | 0 (0) | 9 (69) | 2 (100) | 11 (73) | 11 (19) |
| 2-4           | 0 (0) | 0 (0) | 0 (0) | 3 (23) | 0 (0) | 3 (20) | 3 (5) |
| ≥5            | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 0 (0) | 1 (7) | 1 (2) |
| Total number of nodes examined | | | | | | | |
| 1             | 8 (24) | 4 (44) | 12 (29) | 4 (31) | 1 (50) | 5 (33) | 17 (30) |
| 2             | 6 (18) | 0 (0) | 6 (14) | 3 (23) | 0 (0) | 3 (20) | 9 (16) |
| 3             | 5 (15) | 1 (11) | 6 (14) | 0 (0) | 0 (0) | 0 (0) | 6 (11) |
| 4             | 4 (12) | 0 (0) | 4 (10) | 2 (15) | 0 (0) | 2 (13) | 6 (11) |
| ≥5            | 10 (30) | 4 (44) | 14 (33) | 4 (31) | 1 (50) | 5 (33) | 19 (33) |
| Disease relapse | | | | | | | |
| None          | 33 (100) | 3 (33) | 36 (86) | 9 (69) | 1 (50) | 10 (67) | 46 (81) |
| Local         | 0 (0) | 3 (33) | 3 (7) | 2 (15) | 0 (0) | 2 (13) | 5 (9) |
| Regional      | 0 (0) | 2 (22) | 2 (5) | 0 (0) | 0 (0) | 0 (0) | 2 (4) |
| Distant       | 0 (0) | 1 (11) | 1 (2) | 2 (15) | 1 (50) | 3 (20) | 4 (7) |
| Local, regional, or distant | 0 (0) | 6 (55) | 6 (55) | 4 (36) | 1 (9) | 5 (45) | 11 (100) |
| Median recurrence time (range, months) | | | | | | | |
| -             | 10 (7-12) | 10 (7-12) | 10 (4-48) | 14 | 10 (4-48) | 11 (4-48) |
| Status at last follow-up | | | | | | | |
| Alive without MCC | 26 (79) | 4 (44) | 30 (71) | 6 (46) | 0 (0) | 6 (40) | 36 (63) |
| Alive with MCC  | 0 (0) | 1 (11) | 1 (2) | 1 (8) | 0 (0) | 1 (7) | 2 (4) |
| Died of MCC    | 0 (0) | 1 (11) | 1 (2) | 3 (23) | 0 (0) | 3 (20) | 4 (7) |
| Died of other cause | 7 (21) | 3 (33) | 10 (24) | 3 (23) | 2 (100) | 5 (33) | 15 (26) |

Abbreviations: AJCC = American Joint Committee on Cancer; MCC = Merkel cell carcinoma; SLNB = sentinel lymph node biopsy.

* P < .05. Parentheses contain column percentages except as indicated for ranges and for variables contained within a single row, which represent row percentages.
57.7%, \(P = .164\) compared with SLNB-positive patients who received comprehensive RT. Female sex was associated with improved 4-year OS (100% vs 65%, \(P = .008\)) and DSS (100% vs 80%, \(P = .038\)). No regional recurrences were observed in either group. Patient age, anatomical site, tumor size, immunosuppressed state, polyomavirus positivity, number of positive nodes, and number of nodes examined were not associated with any endpoint in univariate analysis. See Figure 2 for survival curves by SLNB status and treatment.

**Discussion**

In this study, we found that SLNB status was useful for determining the extent of subsequent RT. RT to the primary site was important for optimizing local control. Regional RT may not be necessary in cases of negative SLNB, which demonstrated a low risk of relapse in the nodal bed. For SLNB-positive patients, the 4-year DSS was 65%, LRFS was 76%, and DRFS was 75% despite comprehensive adjuvant RT, underscoring the prognostic importance of SLNB status.

MCC is highly radiosensitive, and a systematic review of more than 17,000 MCC cases across 29 studies identified improved locoregional control and OS with adjuvant RT, even in the lowest-risk subset.\(^9\) However, most studies do not describe the RT details, and other studies question the need for adjuvant RT to small, low-risk lesions.\(^{3,10,11}\) Surgery alone has been associated with a recurrence rate of 26% to 32% after WLE\(^{23,24}\) and even higher rates after limited excision.\(^{25,26}\) One large series reported that among 108 SLNB-negative patients, 2 (2%) were given completion nodal dissection and 9 (8%) underwent nodal RT with or without chemotherapy; subsequently, 9 (8%) of these patients had nodal recurrence, and 6 (6%) had distant recurrences, but, of note and unlike our series, no primary site recurrences occurred.\(^{13,27}\) Among patients in our cohort who had surgery but not adjuvant RT, 50% to 67% (SLNB-positive, \(n = 1/2\); SLNB-negative, \(n = 6/9\)) experienced some form of disease relapse, and among unirradiated SLNB-negative patients, half of these relapses were local failures (33%).

MCC has a propensity to spread to the draining lymph nodes, and accordingly, 27% of patients present with regional disease,\(^{13}\) whereas up to a third present with
occult nodal metastases. The first and only prospective MCC trial randomizing stage I patients to adjuvant nodal RT versus observation of the nodal basin was prematurely terminated due to increasing SLNB use. In the absence of prospective data, reports have suggested that RT to the draining lymph node basin can be omitted for SLNB-negative patients, citing a low risk of regional recurrence. However, in these retrospective studies, regional relapse rates for these patients were 11% to 17% with overall relapse as high as 20% to 30%, and radiation fields were not uniform. In this context, the over-riding goal of our study was to evaluate the low risk of regional recurrence when only the primary site was irradiated after a negative SLNB. In our study of clinically node-negative patients, we observed a zero-failure rate among SLNB-negative patients who underwent postoperative RT to the primary site alone. However, it should be acknowledged that more nodal failures could have been observed with a larger dataset including more patients, particularly because the false negative rate of SLNB in MCC may be as high as 17%. Of note, patients with HN-MCC have been proposed to constitute a high-risk subgroup of SLNB-negative patients. However, prior analyses included patients who had clinical rather than pathologic node evaluation and hence a higher false negative rate. No increased risk of recurrence was found in lymph node-negative HN-MCC evaluated with SLNB. In our cohort, anatomic site was not associated with any outcome, although it should be noted that our study only included patients for whom SLNB was successfully obtained. The only factor in our study influencing 4-year OS was female sex, consistent with previous studies but not all.

Reported relapse rates for SLNB-positive MCC are high, with recurrence rates of 33% to 49% among SLNB-positive patients treated with WLE and adjuvant nodal RT and/or chemotherapy. We confirmed a higher rate of local and distant relapse among these patients, who should be considered for novel therapies. Additionally, these patients were more likely to be immunosuppressed compared with SLNB-negative patients.

It should be noted that we excluded patients where staging was uncertain or SLNB was not successful. The National Comprehensive Cancer Network guidelines advise against overreliance on SLNB if there is high risk for a false negative reading. Reasons for caution include prior large-scale WLE, operator failure or abortive technical factors, inability to conduct complete immunohistochemical analysis, or profound immunosuppression. A history of prior major surgery can complicate drainage patterns particularly in the head and neck region.

A further limitation of this work is the exclusion of patients with incomplete treatment data, including some referred to outside facilities. These patients may systematically differ from the study population reported here. However, we were able to acquire information for
approximately half of these patients and no obvious differences were observed.

In sum, in this single-institution retrospective series, surgical excision followed by adjuvant RT to only the primary site omitting the draining nodal basin provided 100% tumor control for SLNB-negative disease. On the other hand, radiation to the primary site is warranted as omission of this treatment led to a frequent incidence of relapse (67% disease relapse, half being local in nature, in this series). Patients with positive and indeterminant SLNBs had worse outcomes despite comprehensive adjuvant RT, and for them, innovative approaches are needed.

References

1. Pulitzer MP, Amin BD, Busam KJ. Merkel cell carcinoma: Review. Adv Anat Pathol. 2009;16:135–144.
2. Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78:457–463.e2.
3. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: Prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23:2300–2309.
4. Bichakjian CK, Olencki T, Aasi SZ, et al. Merkel cell carcinoma, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:742–774.
5. Gupta SG, Wang LC, Penas PF, et al. Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. Arch Dermatol. 2006;142:685–690.
6. Grotz TE, Joseph RW, Pockaj BA, et al. Negative sentinel lymph node biopsy in merkel cell carcinoma is associated with a low risk of same-nodal-basin recurrences. Ann Surg Oncol. 2015;22:4060–4066.
7. Jenkins LN, Howle JR, Veness MJ. Sentinel lymph node biopsy in clinically node-negative Merkel cell carcinoma: The Westmead Hospital experience. ANZ J Surg. 2019;89:520–523.
8. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165:710–718.
9. Peterli R, Ghidini A, Torchio M, et al. Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. Radiother Oncol. 2019;134:211–219.
10. Kim JA, Choi AH. Effect of radiation therapy on survival in patients with resected Merkel cell carcinoma: A propensity score surveillance, epidemiology, and end results database analysis. JAMA Dermatol. 2013;149:831–838.
11. Frohn ML, Griffith KA, Harms KL, et al. Recurrence and survival in patients with merkel cell carcinoma undergoing surgery without adjuvant radiation therapy to the primary site. JAMA Dermatol. 2016;152:1001–1007.
12. Jouary T, Leyral C, Dreno B, et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: A multicentric prospective randomized study. Ann Oncol. 2012;23:1074–1080.
13. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49:832–841.
14. Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63:751–761.
15. Gunaratne DA, Howle JR, Veness MJ. Sentinel lymph node biopsy in Merkel cell carcinoma: A 15-year institutional experience and statistical analysis of 721 reported cases. Br J Dermatol. 2016;174:273–281.
16. Smith VA, Camp ER, Lentsch EJ. Merkel cell carcinoma: Identification of prognostic factors unique to tumors located in the head and neck based on analysis of SEER data. Laryngoscope. 2012;122:1283–1290.
17. Hitchcock CL, Bland KI, Laney RG, et al. Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment. Ann Surg. 1988;207:201–207.
18. Kukko H, Bohling T, Koljonen V, et al. Merkel cell carcinoma - A population-based epidemiological study in Finland with a clinical series of 181 cases. Eur J Cancer. 2012;48:737–742.
19. Liang E, Brower JV, Rice SR, et al. Merkel cell carcinoma analysis of outcomes: A 30-year experience. PLoS One. 2015;10:e0129476.
20. Allen PJ, Zhang ZF, Coit DG. Surgical management of Merkel cell carcinoma. Ann Surg. 1999;229:97–105.
21. Mehrany K, Otley CC, Weenig RH, et al. A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. Dermatol Surg. 2002;28:113–117. [discussion 117].
22. Hoeller U, Mueller T, Schubert T, et al. Regional nodal relapse in surgically staged Merkel cell carcinoma. Strahlenther Onkol. 2015;191:51–58.
23. Yiengpruksawan A, Coit DG, Thaler HT, Urmacher C, Knapper WK. Merkel cell carcinoma. Prognosis and management. Arch Surg. 1991;126:1514–1519.
24. Brissett AE, Olsen KD, Kasperbauer JL, et al. Merkel cell carcinoma of the head and neck: a retrospective case series. Head Neck. 2002;24:982–988.
25. O’Connor WJ, Roenigk RK, Brodland DG. Merkel cell carcinoma. Comparison of Mohs micrographic surgery and wide excision in eighty-six patients. Dermatol Surg. 1997;23:929–933.
26. Hohaus K, Kostler E, Schönlbe J, Klemm E, Wollina U. Merkel cell carcinoma: a retrospective analysis of 17 cases. J Eur Acad Dermatol Venereol. 2003;17:20–24.
27. Fields RC, Busam KJ, Chou JF, et al. Recurrence and survival in patients undergoing sentinel lymph node biopsy for Merkel cell carcinoma: analysis of 153 patients from a single institution. Ann Surg Oncol. 2011;18:2529–2537.